Three AIM Listed Pharmaceutical Stocks Making the Waves – Immupharma Plc, Optibiotix Health Plc and Indivior Plc

  • Nov 30, 2019 GMT
  • Team Kalkine
Three AIM Listed Pharmaceutical Stocks Making the Waves – Immupharma Plc, Optibiotix Health Plc and Indivior Plc

Immupharma Plc

Immupharma Plc (LON: IMM) is a London, the United Kingdom based Pharmaceuticals and Biotechnology company that is involved in the business of Research as well as production and development of various drugs which are used for multiple clinical diseases. The company also develops new and innovative therapies for specialist diseases which are basically featured by the company to serve the high unmet medical need, and have low development and marketing costs. The company leverages the Centre National de la Recherche Scientifique (National Center for Scientific Research) (CNRS) for their market leading and dynamic research. The company’s portfolio of developed drugs primarily includes Lupuzor, which is a Lead product in late-stage clinical trial, and drugs for Auto-immune diseases, Oncology and Ophthalmology, as well as Metabolism and Diabetes.

IMM Latest News

On 28th November 2019, the company made a press release to announce its License and development agreement, as well as a trademark agreement for its flagship product Lupuzor with Avion Pharmaceuticals LLC. Using this agreement, the company hopes to establish a presence in the United States of America as the license and development agreement enables Avion with the exclusive rights to sell Lupuzor in the United States of America. The company also highlighted that the two companies will develop the drug Lupuzor™ together for the purposes of registration of marketing in the United States, European region and other places in the world. The company also emphasised the fact that Avion has the sole right to leverage appropriate trademarks for the development, production as well as marketing of the products.

IMM Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 29-November-19, prior to the close of the market

On 29th November 2019, at 01:45 P.M GMT, while writing, Immupharma Plc’s share price was reported to be at GBX 23.2 per share, a decline of 17.14 per cent or GBX 4.80 per share, as compared to the previous day’s closing price, which was reported to be at GBX 28.00 per share. At the time of reporting, the Immupharma Plc share was reported to be trading 235.75 per cent above the 52-week low share price, which was at GBX 6.91 per share, that the company’s shares reached on November 27, 2019. The company’s market capitalisation (M-Cap) was reportedly valued to be at GBP 46.86 million with respect to the share’s current market price.

The Immupharma Plc share has depicted a positive change in the last six months in the value of around 107.14 per cent from the share price of GBX 11.20 per share that the company’s share achieved on May 29, 2019. Immupharma Plc’s share has also risen by 160.67 per cent in value, in the last one month from the price of GBX 8.90 per share that the shares closed at on October 29, 2019.

The beta of the Immupharma Plc’s share has been reported to be at 0.82. This basically implies that the volatility in the price of the company’s stock, is more than the volatility in the movement of the comparative benchmark index.

Optibiotix Health Plc

Optibiotix Health Plc (LON: OPTI) is the United Kingdom based company that is engaged in the life sciences space and indulges in the research and production around microbiome modulators. The company identifies and develops a range of products to modify the human microbiome. The company has six major products, which are SlimBiome®, SlimBiome Medical ®, LP LDL®, Chol Biome®, LP GOS® and Sweet Biotix, which are all utilised as microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression.

OPTI Latest News

On 9th October 2019, the company made a press release to announce the LPLDL® Pharmaceutical GMP process validation. The company reported that one of its wholly owned subsidiaries, called ProBiotix Health limited has completed the process validation under Pharmaceutical Good Manufacturing Practices, for the above mentioned drug and has received the safety certificate issued by the United States Food and Drug Administration (FDA).

OPTI Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 29-November-19, prior to the close of the market

On 29th November 2019, at 01:50 P.M GMT, while writing, Optibiotix Health Plc’s share price was reported to be at GBX 52.45 per share, a decline of 0.10 per cent or GBX 0.05 per share, as compared to the previous day’s closing price, which was reported to be at GBX 52.50 per share. At the time of reporting, the Optibiotix Health Plc share was reported to be trading 24.88 per cent above the 52-week low share price, which was at GBX 42.00 per share, that the company’s shares reached on September 10, 2019. The company’s market capitalisation (M-Cap) was reportedly valued to be at GBP 44.86 million with respect to the share’s current market price.

The Optibiotix Health Plc share has depicted a negative change in the last six months in the value, of around 40.06 per cent from the share price of GBX 87.5 per share that the company’s share achieved on May 29, 2019. Optibiotix Health Plc’s share has also declined by 22.30 per cent in value, in the last one month from the price of GBX 67.5 per share that the shares closed at on October 29, 2019.

The beta of the Optibiotix Health Plc’s share has been reported to be at 0.96. This basically implies that the volatility in the price of the company’s stock, is less than the volatility in the movement of the comparative benchmark index.

Indivior Plc

Indivior Plc (LON: INDV) is a Slough, the United Kingdom based expert pharmaceutical organisation, with central command in North Chesterfield, Virginia, USA. In the year 1994, the organisation joined as the Buprenorphine division of Reckitt Benckiser, concentrating on assembling of a narcotic used to treat narcotic dependence, intense torment, and constant agony. In December 2014 it was sun to an autonomous organisation as Indivior, which was accordingly, in February 2015 listed on the London Stock Exchange. The organization's business tasks incorporate creating, assembling, and selling professionally prescribed medications as utilized for the treatment of narcotic reliance. The organisation has predominance in fixation treatment with more than 20 years of rich experience. Its two geographical divisions are the United States and the Rest of the World.

INDV Financial Performance

On 31st October 2019, the company announced its results for the third quarter as well as 9 months ended to 30th September 2019. It was reported that the revenue for the year to date period stood at US $652 million, a year on year 15 per cent decline (Actual Basis) compared to the same period in the previous year when the revenue was reported at US 768 million. The Revenue for the third quarter was also reported at a decline of 19 per cent (Actual Basis) year on year to US $199 million compared to US $245 million in Q3 2018.

Period to Sept. 30th Q3 Q3 % ∆ % ∆ YTD YTD % ∆ % ∆
2019 2018 Actual Constant 2019 2018 Actual Constant
$m $m FX FX $m $m FX FX
Net Revenue 199 245 -19 -18 652 768 -15 -14
Operating Profit 57 71 -20 -16 220 271 -19 -17
Net Income 48 89 -46 -44 189 251 -25 -23
EPS (cents/share) 7 12 -42 -44 26 35 -26 -23
                 
Adj. Operating Profit* 57 71 -20 -16 248 254 -2 -
Adj. Net Income* 48 58 -17 -14 213 205 4 6
Adj. Basic EPS* 7 8 -13 -14 29 28 4 6

Source: Company Website

INDV Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 29-November-19, prior to the close of the market

On 29th November 2019, at 01:58 P.M GMT, while writing, Indivior Plc’s share price was reported to be at GBX 40.05 per share, an increase of 2.69 per cent or GBX 1.05 per share, as compared to the previous day’s closing price, which was reported to be at GBX 39.00 per share. At the time of reporting, the Indivior Plc share was reported to be trading 90.90 per cent above the 52-week low share price, which was at GBX 20.98 per share, that the company’s shares reached on April 10, 2019. The company’s market capitalisation (M-Cap) was reportedly valued to be at GBP 284.99 million with respect to the share’s current market price.

The Indivior Plc share has depicted a negative change in the last six months in the value, of around 10.92 per cent from the share price of GBX 44.96 per share that the company’s share achieved on May 29, 2019. Indivior Plc’s share has also declined by 6.80 per cent in value, in the last one month from the price of GBX 42.97 per share that the shares closed at on October 29, 2019.

The beta of the Indivior Plc’s share has been reported to be at 0.79. This basically implies that the volatility in the price of the company’s stock, is less than the volatility in the movement of the comparative benchmark index.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK